MSD launches new manufacturing facilities in Singapore

October 7, 2022
MSD (trade name of Merck & Co., Inc.) has opened a new secondary packaging facility in Singapore, the home of MSD’s Asia Pacific hub. The secondary packaging facility is expected to support the production of vaccines and biologics, including the company’s cancer immunotherapy products.  MSD also broke ground for a new inhaler production facility for the manufacture of new generation inhaler medicines in Singapore.  Both manufacturing facilities are key components of the company’s up to US$500 million investment over five years that started in 2020 – in addition to the US$2 billion invested since the start of MSD’s manufacturing operations in Singapore in 1997.  Other components of the US$500 million investment include incorporation of new technology to further MSD’s environmental sustainability goals, and modernisation of MSD’s information technology (IT) infrastructure in support of digitising the facilities.  The opening of the new secondary packaging facility and ground-breaking for the inhaler production facility was witnessed by Singapore’s Minister for Trade & Industry and Guest-of-Honour, Gan Kim Yong, and Robert Davis, CEO and President of MSD.  The new facilities are located within MSD’s existing 72-acre, multi-product manufacturing hub in Tuas. The secondary packaging facility will house a semi-automated, vial-packaging line to produce immunotherapy drug Keytruda (pembrolizumab), and three fully automated syringe-packaging lines to produce the company’s HPV recombinant vaccine, Gardasil.  In 2021, the site commenced the sterile filling process of the immunotherapy drug vials. Secondary packaging, cold storage, and a quality control laboratory will be a part of the expanded facility which further adds to the supply chain footprint for this product in Singapore.  Meanwhile, the new inhaler medicine facility, when ready in 2026, will manufacture next generation inhaler devices for targeted administration of medicines.  “MSD is committed to Singapore as a strategic node in our company’s global manufacturing network with a focus on producing innovative medicines to treat chronic diseases and cancer as well as vaccines that prevent infectious diseases for patients living in Singapore and throughout the Asia Pacific region and beyond,” said Fernando Otero, Associate VP, MSD Manufacturing Division, Singapore.  “The talent, research, and technology capabilities that first attracted our company to Singapore has been a key incentive for our continuing investment. We’re delighted to further invest in building technologically advanced facilities and highly skilled manufacturing here,” he added.  The multi-year investment plan is estimated to create over 100 new jobs over the next few years to support the new facility, with many positions requiring advanced manufacturing and digital skills. This would bring the company’s total employees in Singapore to more than 1,800 over the next few years.  In a closing note, David Peacock, President, Asia Pacific, MSD, said, “MSD has been in Singapore since 1993 and continues to invest significantly in Singapore to impact patients worldwide through our innovative medicines and vaccines.  “The launch of the new secondary packaging facility and ground-breaking for the new inhaler facility today highlights the value that biopharmaceutical innovation brings to Singapore, contributing to the health and wellbeing of the nation and the region. It further demonstrates our commitment to making a difference by bringing our medicines and vaccines to people as quickly as possible, while ensuring that the Asia Pacific region is well-positioned to manage future healthcare challenges.”

MSD (trade name of Merck & Co., Inc.) has opened a new secondary packaging facility in Singapore, the home of MSD’s Asia Pacific hub. The secondary packaging facility is expected to support the production of vaccines and biologics, including the company’s cancer immunotherapy products.

MSD also broke ground for a new inhaler production facility for the manufacture of new generation inhaler medicines in Singapore.

Both manufacturing facilities are key components of the company’s up to US$500 million investment over five years that started in 2020 – in addition to the US$2 billion invested since the start of MSD’s manufacturing operations in Singapore in 1997.

Other components of the US$500 million investment include incorporation of new technology to further MSD’s environmental sustainability goals, and modernisation of MSD’s information technology (IT) infrastructure in support of digitising the facilities.

The opening of the new secondary packaging facility and ground-breaking for the inhaler production facility was witnessed by Singapore’s Minister for Trade & Industry and Guest-of-Honour, Gan Kim Yong, and Robert Davis, CEO and President of MSD.

MSD launches new manufacturing facilities in Singapore

The new facilities are located within MSD’s existing 72-acre, multi-product manufacturing hub in Tuas. The secondary packaging facility will house a semi-automated, vial-packaging line to produce immunotherapy drug Keytruda (pembrolizumab), and three fully automated syringe-packaging lines to produce the company’s HPV recombinant vaccine, Gardasil.

In 2021, the site commenced the sterile filling process of the immunotherapy drug vials. Secondary packaging, cold storage, and a quality control laboratory will be a part of the expanded facility which further adds to the supply chain footprint for this product in Singapore.

Meanwhile, the new inhaler medicine facility, when ready in 2026, will manufacture next generation inhaler devices for targeted administration of medicines.

“MSD is committed to Singapore as a strategic node in our company’s global manufacturing network with a focus on producing innovative medicines to treat chronic diseases and cancer as well as vaccines that prevent infectious diseases for patients living in Singapore and throughout the Asia Pacific region and beyond,” said Fernando Otero, Associate VP, MSD Manufacturing Division, Singapore.

“The talent, research, and technology capabilities that first attracted our company to Singapore has been a key incentive for our continuing investment. We’re delighted to further invest in building technologically advanced facilities and highly skilled manufacturing here,” he added.

The multi-year investment plan is estimated to create over 100 new jobs over the next few years to support the new facility, with many positions requiring advanced manufacturing and digital skills. This would bring the company’s total employees in Singapore to more than 1,800 over the next few years.

In a closing note, David Peacock, President, Asia Pacific, MSD, said, “MSD has been in Singapore since 1993 and continues to invest significantly in Singapore to impact patients worldwide through our innovative medicines and vaccines.

“The launch of the new secondary packaging facility and ground-breaking for the new inhaler facility today highlights the value that biopharmaceutical innovation brings to Singapore, contributing to the health and wellbeing of the nation and the region. It further demonstrates our commitment to making a difference by bringing our medicines and vaccines to people as quickly as possible, while ensuring that the Asia Pacific region is well-positioned to manage future healthcare challenges.”

Tags:

Category: Community

Comments are closed.

Subscribe to HCA for exclusive updates

Top Viewed News

12 simple steps to a healthy lifestyle

12 simple steps to a healthy lifestyle

Now that the world has returned to normalcy following the pandemic, everyone is back to their daily routines and encounters with stress... Read More

AZBIL: Envisioning the Future of Hospitals

AZBIL: Envisioning the Future of Hospitals

As we strive to be the hospital of choice, why not refine our commitment to excellence beyond the pivotal mission of saving lives?... Read More

Study Unlocks Key Findings on Asian Carriers of Breast Cancer

Study Unlocks Key Findings on Asian Carriers of Breast Cancer

Malaysian researchers at Cancer Research Malaysia (CRMY) and the University of Nottingham Malaysia (UNM) have published... Read More

 Unmasking the Risks of Mercury-Laden Cosmetics

Unmasking the Risks of Mercury-Laden Cosmetics

As the saying goes, beauty is in the eye of the beholder and thus subjective; but in some countries, the ideal of beauty begins... Read More

5 key hospital etiquettes to be mindful of when visiting a sick patient

5 key hospital etiquettes to be mindful of when visiting a sick patient

In moments of illness, the presence of loved ones can comfort and support. However, it’s important for visitors... Read More

Free counters!

2025 – 2026 Exhibitions



2025 Events


9-11 July
Medical Device Development (MEDIX) – Osaka
Makuhari Messe, Japan
www.manufacturing-world.jp


14-16 July
Lab Asia
Kuala Lumpur Convention Centre (KLCC), Malaysia
www.lab-asia.com


16-18 July
Medlab Asia | Asia Health
Malaysia International Trade & Exhibition Centre, Kuala Lumpur
www.medlabasia.com


24 July
Medlab Asia | Asia Health
Singapore
www.conversationaltechsummitasia.com


13-15 August
Philippines Medical
SMX Convention Center Manila Philippines
www.philmedical.com


21-23 August
REHACARE China
Suzhou, China
www.rehacare-c.com


21-23 August
Medical Fair China
Suzhou, China
www.medicalfair.cn


3-5 September
Thailand Lab International
BITEC, Bangkok, Thailand
www.thailandlab.com


3-5 September
Bio Ap International
BITEC, Bangkok
www.bioapinter.com


9-12 September
China Dental Show
National Exhibition and Convention Center (Shanghai)
www.chinadentalshow.com


10-11 September
Hospital Management Asia
Shangri-La Kuala Lumpur, Malaysia
www.hospitalmanagementasia.com


10-12 September
Medical Fair Thailand
BITEC, Bangkok
www.medicalfair-thailand.com


10-12 September
GITEX Digi Health & Biotech Thailand
BITEC, Bangkok
www.www.gitexdigihealth.com


11-13 September
Bio Asia Pacific
BITEC, Bangkok
www.bioasiapacific.com


16-18 September
OSH India
Hall-6, Bombay Exhibition Centre, Goregaon (E)
www.oshindia.com


24-26 September
Medtec China
Shanghai, China
www.en.medtecchina.com


7-9 October
Malaysia Pharma and Healthcare Expo
Kuala Lumpur, Malaysia
www.mphcexpo.com


9-11 October
Medical Japan Tokyo
Makuhari Messe, Japan
www.medical-jpn.jp


17-19 October
Health Asia
BITEC, Bangkok
www.health-asia.com


17-19 October
Health Asia
BITEC, Bangkok
www.health-asia.com


29-30 October
United Medical Expo
Astana, Kazakhstan
www.umtexpo.com


7-8 November
Eldercare Exhibition and Conference Asia (ELDEX Asia)
Suntex Singapore Exhibition and Convention Centre
www.eldexasia.com


10-12 November
Saudi International Pharma Expo
Riyadh International Convention and Exhibition Center
www.saudipharmaexpo.com


10-12 November
Saudi International MedLab Expo
Riyadh International Convention and Exhibition Center
www.saudimedlabexpo.com


27-29 November
International Wellness Expo (IWE 2025)
METIC, Malaysia
www.internationalwellnessexpo.com


27-29 November
Vietnam Medi-Pharm
Friendship Cultural Palace , Hanoi
www.vietnammedipharm.vn


2026 Events


9-12 Febuary
Arab Health
Dubai World Trade Centre
www.arabhealthonline.com


15-17 April
Lab Indonesia
Jakarta Convention Center, Jakarta, Indonesia
www.lab-indo.com


28-30 April
SEACare
MITEC, KL
wwww.ea-healthcare.com


6-7 May
HealthTechX Asia
Sands Expo & Convention Centre, Singapore
www.healthtechx-asia.com


4-6 June
International Health Industry Expo
China
www.ihe-china.com


16-18 June
CPhI China
SNIEC, Shanghai, China
www.cphi.com


25-27 June
Medical Taiwan
Taipei Nangang Exhibition Center, Taipei, Taiwan
www.medicaltaiwan.com.tw


9-11 September
Medical Fair Asia
Marina Bay Sands, Singapore
www.medicalfair-asia.com


9-11 September
Medical Manufacturing Asia
Marina Bay Sands, Singapore
www.medmanufacturing-asia.com


1-2 October
GITEX Vietnam
Hanoi
www.gitexasia.com